Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
STOCKHOLM, Sept. 1, 2026 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.